Roche Diagnostics Corporation

Roche Diagnostics Corporation, a foreign-owned manufacturer headquartered in Indianapolis, Indiana, supplies in vitro diagnostic equipment, laboratory analyzers, reagents, and clinical testing consumables to federal healthcare agencies as a prime contractor, competing on full-and-open basis across government-wide and agency-specific contract vehicles without small-business set-asides. The vendor is a subsidiary of Foundation Medicine, Inc., a foreign-owned diagnostic solutions parent company.

Roche's federal footprint centers on clinical laboratory diagnostics and automated testing systems. Recent representative work includes a $5.37 million delivery order from Veterans Integrated Service Network 10 for Roche Ventana reagents supporting Cleveland Veterans Affairs Medical Center (March 2026); a $1.74 million delivery order from the Defense Health Agency for fully automated histology sample preparation and consultation system at Brooke Army Medical Center, Fort Sam Houston, Texas (October 2026); and a $2.46 million delivery order from the Defense Health Agency for clinical laboratory diagnostic equipment and services at Fort Sam Houston (October 2026). The vendor supplies molecular diagnostic analyzers (COBAS 5800/6800 platforms), histology staining systems (Ventana and Benchmark series), chemistry and immunoassay analyzers, point-of-care testing devices (Accu-Chek, ePlex systems), specialized reagents, and maintenance and support services across federal healthcare networks.

Customer concentration runs heavily toward the Veterans Health Administration and military healthcare providers. The top five customer agencies by award count represent 15 percent of Roche's recent awards and include the Department of Veterans Affairs (614 awards), Indian Health Service (541 awards), Army Medical Command (479 awards), Navy Bureau of Medicine and Surgery (467 awards), and VISN 10 (429 awards). When ranked by potential dollar value, the Defense Health Agency leads with $414.2 million across 379 awards, followed by Centers for Disease Control and Prevention ($295 million, 405 awards), VISN 8 ($223 million, 264 awards), Army Medical Command ($215.6 million, 479 awards), and VISN 22 ($180.5 million, 302 awards). The two rankings diverge slightly—DHA anchors dollar volume while VA's distributed network of VISNs dominates award count—but both reflect sustained federal demand for diagnostic capabilities across healthcare delivery systems.

Roche positions itself primarily through GSA Schedules and indefinite delivery vehicles. The top three parent vehicles are the Critical Analyzers, Laboratory schedule (FSS-66-III) with 2,426 task orders worth $1.06 billion in combined potential value, Federal Supply Schedule V797P5472X (Roche's primary catalog schedule) with 2,217 task orders valued at $156.1 million, and the In Vitro Diagnostics, Reagents, Test schedule (FSS-65-VII) with 954 task orders worth $91.9 million. These vehicles enable rapid ordering by federal agencies without re-competition. Additionally, Roche holds single-award indefinite delivery contracts and blanket purchase agreements with individual VISNs; representative recent examples include an $8.9 million IDIQ with VISN 22 for Roche 5800 CPT laboratory diagnostic systems (March 2026, through March 2031), a $7.5 million IDIQ with VISN 20 for reference laboratory services at Portland VA (February 2026, through November 2030), and a $17.2 million Warfighter Screening BPA with the Air Force (April 2026, through April 2031). Sole-source justifications frequently cite equipment compatibility and proprietary reagent ecosystem—the government's determination that only Roche supplies proprietary consumables compatible with Roche-owned instruments already deployed at VA facilities.

Activity has remained relatively flat over the past five years, with 341 awards in 2022 declining to 208 in 2026 year-to-date (through October 2)—a slight downward trend but within normal procurement variance for a vendor of this size and federal reliance. The vendor faces a recompete cliff of $136.9 million across 193 awards completing within the next twenty-four months, representing material opportunity for competitors pursuing task order displacement or incumbent recompete challenge.

Roche's award portfolio spans 16,764 total awards with combined potential value of $5.57 billion, of which $2.16 billion is obligated (39 percent). The vendor competes almost exclusively as prime (99.9 percent of awards); sub-award activity is negligible (10 sub-awards across the portfolio). NAICS concentration reflects the vendor's core business: In-Vitro Diagnostic Substance Manufacturing (NAICS 325413) accounts for 5,641 awards, and Analytical Laboratory Instrument Manufacturing (NAICS 334516) for 3,977 awards. PSC coding shows similar focus—Laboratory Equipment and Supplies (PSC 6640) and In Vitro Diagnostic Substances, Reagents, Test Kits (PSC 6840) dominate. Service Contract Inventory data is sparse for this vendor (29 SCI records across FY2022–FY2025, with only $82 thousand in invoiced revenue in FY2023); SCI captures only service contracts above $150,000 threshold and excludes goods and products that form the bulk of Roche's federal deliveries. The minimal SCI footprint reflects the vendor's dominance in product sales—laboratory equipment, analyzers, and reagents—rather than service-based engagement.

Roche operates as a pure product supplier with no material subcontracting. It builds no teaming partnerships or joint ventures on its federal portfolio; all work is direct from Roche to the customer. The vendor's federal strategy centers on proprietary equipment lock-in (Ventana, Benchmark, COBAS platforms) combined with sole-source reagent supply justifications, leveraging GSA Schedule pricing to reduce customer procurement friction and enable rapid task-order issuance. Competition risk is mitigated by brand ecosystem defensibility—once a federal lab deploys a Roche analyzer, switching costs and workflow disruption make competitive displacement difficult, anchoring renewal and expansion work to the incumbent supplier.